US 11,970,543 B2
Anti-CD39 antibodies and use thereof
Christine Elizabeth Bowman, San Francisco, CA (US); Ada Pei Xian Chen, San Francisco, CA (US); Ester Fernandez-Salas, San Mateo, CA (US); Nigel Pelham Clinton Walker, Burlingame, CA (US); Xiaoning Zhao, San Jose, CA (US); Yaohua Hu, Shanghai (CN); Siwei Nie, Shanghai (CN); and JijIe Gu, Shanghai (CN)
Assigned to ARCUS BIOSCIENCES, INC., Hayward, CA (US); and WUXI BIOLOGICS IRELAND LIMITED, Mullagharlin (IE)
Filed by ARCUS BIOSCIENCES, INC., Hayward, CA (US); and WUXI BIOLOGICS IRELAND LIMITED, Mullagharlin (IE)
Filed on Mar. 2, 2023, as Appl. No. 18/177,729.
Prior Publication US 2024/0034803 A1, Feb. 1, 2024
Int. Cl. A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)] 13 Claims
 
1. An anti-CD39 antibody that specifically binds to human CD39, comprising a heavy chain variable region comprising a complementarity determining region 1 (H1) comprising SEQ ID NO: 28, a complementarity determining region 2 (H2) comprising SEQ ID NO: 29, and a complementarity determining region 3 (H3) comprising SEQ ID NO: 30; and a light chain variable region comprising a complementarity determining region 1 (L1) comprising SEQ ID NO: 32, a complementarity determining region 2 (L2) comprising SEQ ID NO: 33, and a complementarity determining region 3 (L3) comprising SEQ ID NO: 34.